MEN16132, a kinin B2 receptor antagonist, prevents the endogenous bradykinin effects in guinea-pig airways

European Journal of Pharmacology

Volumn 579, Issue 1-3, 2008, Pages 350-356

  Valenti, Claudio ^a   Cialdai, Cecilia ^a   Giuliani, Sandro ^a   Tramontana, Manuela ^a   Quartara, Laura ^b   Maggi, Carlo Alberto ^a  

^a Pharmacology Department   (Italy)

^b Menarini Ricerche SpA   (Italy)

Author keywords

Airways; Bradykinin; Bronchoconstriction; Dextran sulfate; Kinin B2 receptor antagonist; Plasma protein extravasation

Indexed keywords

BRADYKININ; BRONCHODILATING AGENT; EVANS BLUE; ICATIBANT; KININ B2 RECEPTOR ANTAGONIST; MEN 16132; PIPERAZINE DERIVATIVE; PLASMA PROTEIN; UNCLASSIFIED DRUG; (4 AMINO 5 (4 (4 (2,4 DICHLORO 3 (2,4 DIMETHYL 8 QUINOLYLOXYMETHYL)PHENYLSULFONAMIDO)TETRAHYDRO 2H 4 PYRANOYLCARBONYL)PIPERAZINO) 5 OXOPENTYL)(TRIMETHYL)AMMONIUM; (4-AMINO-5-(4-(4-(2,4-DICHLORO-3-(2,4-DIMETHYL-8-QUINOLYLOXYMETHYL)PHENYLSULFONAMIDO)TETRAHYDRO-2H-4-PYRANOYLCARBONYL)PIPERAZINO)-5-OXOPENTYL)(TRIMETHYL)AMMONIUM; BRADYKININ B2 RECEPTOR; DEXTRAN SULFATE; DRUG DERIVATIVE; ORNITHINE; SULFONAMIDE;

AIRWAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHOSPASM; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; GUINEA PIG; KALLIKREIN KININ SYSTEM; LUNG VENTILATION; MALE; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; AEROSOL; ANIMAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; INTRANASAL DRUG ADMINISTRATION; METABOLISM;

ADMINISTRATION, INTRANASAL; AEROSOLS; ANIMALS; BLOOD PROTEINS; BRADYKININ; BRONCHOCONSTRICTION; DEXTRAN SULFATE; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; KALLIKREIN-KININ SYSTEM; MALE; NASAL MUCOSA; ORNITHINE; RECEPTOR, BRADYKININ B2; SULFONAMIDES;

EID: 37649008332     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.10.025     Document Type: Article

References (55)

1. Abraham W.M., Scuri M., and Farmer S.G. Peptide and non-peptide bradykinin receptor antagonists: role in allergic airway disease. Eur. J. Pharmacol. 533 (2006) 215-221
2. Akbary A.M., Wirth K.J., and Scholkens B.A. Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma. Immunopharmacology 33 (1996) 238-242
3. Arai Y., Takanoshi H., Kitagawa H., Wirth K.J., and Okayasu I. Effect of Icatibant, a bradykinin B2 receptor antagonist, on the development of experimental ulcerative colitis in mice. Dig. Dis. Sci. 44 (1999) 845-851
4. 2 kinin receptor antagonist, of antigen-induced nasal blockage. Br. J. Pharmacol. 111 (1994) 969-971
5. Baraniuk J.N., Lundgren J.D., Mizoguchi H., Peden D., Gawin A., Merida M., Shelhamer J.H., and Kaliner M.A. Bradykinin and respiratory mucous membranes. Analysis of bradykinin binding site distribution and secretory responses in vitro and in vivo. Am. Rev. Respir. Dis. 141 (1990) 706-714
6. Baumgarten C.R., Togias A., Naclerio R.M., Lichtenstein L.M., Norman P.S., and Proud D. Influx of kininogens in nasal secretions after antigen challenge of allergic individuals. J. Clin. Invest. 76 (1985) 191-197
7. Baumgarten C.R., Nichols R.C., Naclerio R.M., and Proud D. Concentrations of glandular kallikrein in human nasal secretions increase during experimentally induced allergic rhinitis. J. Immunol. 137 (1986) 1323-1328
8. Beckett P.A., and Howarth P.H. Pharmacotherapy and airway remodelling in asthma. Thorax 58 (2003) 163-174
9. Bergeron C., and Boulet L.P. Structural changes in airway diseases: characteristics, mechanisms, consequences and pharmacologic modulation. Chest 129 (2006) 1068-1087
10. Brunnée T., Reddigari S.R., Shibayama Y., Kaplan A.P., and Silverberg M. Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin. Exp. Allergy 27 (1997) 653-663
11. Campbell D.J., Krum H., and Esler M.D. Losartan increases bradykinin levels in hypertensive humans. Circulation 111 (2005) 315-320
12. Christiansen S.C., Proud D., Sarnoff R.B., Juergens U., Cochrane C.G., and Zuraw B.L. Elevation of tissue kallikrein and kinin in the airways of asthmatic subjects after endobronchial allergen challenge. Am. Rev. Respir. Dis. 145 (1992) 900-905
13. Churchill L., Pongracic J.A., Reynolds C.J., Naclerio R.M., and Proud D. Pharmacology of nasal provocation with bradykinin: studies of tachyphylaxis, cyclooxygenase inhibition, α-adrenergic stimulation and receptor subtype. Int. Arch. Allergy Appl. Immunol. 95 (1991) 322-331
14. 2 receptor. In vitro pharmacology and molecular characterization. Eur. J. Pharmacol. 528 (2005) 7-16
15. Driamov S., Bellahcene M., Ziegler A., Barbosa V., Traub D., Butz S., Buser P.T., and Zaugg C.E. Antiarrhythmic effect of ischemic preconditioning during low-flow ischemia. The role of bradykinin and sarcolemmal versus mitochondrial ATP-sensitive K(+) channels. Basic Res. Cardiol. 99 (2004) 299-308
16. Farmer S.G., Wilkins D.E., Meeker S.A., Seeds E.A.M., and Page C.P. Effects of bradykinin receptor antagonists on antigen-induced respiratory distress, airway hyperresponsiveness and eosinophilia in guinea-pigs. Br. J. Pharmacol. 107 (1992) 653-659
17. Fox A.J., Barnes P.J., Urban L., and Dray A. An in vitro study of the properties of single vagal afferents innervating guinea-pig airways. J. Physiol. 469 (1993) 21-35
18. Ghebrehiwet B., Randazzo B.P., Dunn J.T., Silverberg M., and Kaplan A.P. Mechanisms of activation of the classical pathway of complement by Hageman Factor fragment. J. Clin. Invest. 71 (1983) 1450-1456
19. Gosens R., Grootte Bromhaar M.M., Maarsingh H., ten Damme A., Meurs H., Zaagsma J., and Nelemans S.A. Bradykinin augments EGF-induced airway smooth muscle proliferation by activation of conventional protein kinase C isoenzymes. Eur. J. Pharmacol. 535 (2006) 253-262
20. 2 receptor antagonist, on allergic airway disease models. Eur. J. Pharmacol. 467 (2003) 197-203
21. Howl J., and Payne S.J. Bradykinin receptors as a therapeutic target. Expert Opin. Ther. Targets 7 (2003) 277-285
22. 2 receptor. Am. Rev. Respir. Dis. 142 (1990) 1104-1107
23. Ichinose M., Belvisi M.G., and Barnes P.J. Bradykinin-induced bronchoconstriction in guinea-pig in vivo: role of neural mechanisms. J. Pharmacol. Exp. Ther. 253 (1990) 594-599
24. Imamura T., Potempa J., and Travis J. Activation of the kallikrein-kinin system and release of new kinins through alternative cleavage of kininogens by microbial and human cell proteinases. Biol. Chem. 385 (2004) 989-996
25. 2 antagonist: in vitro and in vivo studies. Can. J. Physiol. Pharm. 75 (1997) 622-628
26. Ito H., Hayashi I., Izumi T., and Majima M. Bradykinin inhibits development of myocardial infarction through B2 receptor signalling by increment of regional blood flow around the ischaemic lesions in rats. Br. J. Pharmacol. 138 (2003) 225-233
27. Jin L.S., Seeds E., Page C.P., and Schachter M. Inhibition of bradykinin-induced bronchoconstriction in the guinea-pig by a synthetic B2 receptor antagonist. Br. J. Pharmacol. 97 (1989) 598-602
28. 2 receptor antagonist-treated rats. Jpn. J. Pharmacol. 90 (2002) 59-66
29. Kaplan A.P., Joseph K., and Silverberg M. Pathways for bradykinin formation and inflammatory disease. J. Allergy Clin. Immunol. 109 (2002) 195-209
30. Koyama S., Sato E., Nomura H., Kubo K., Miura M., Yamashita T., Nagai S., and Izumi T. Bradykinin stimulates type II alveolar cells to release neutrophil and monocyte chemotactic activity and inflammatory cytokines. Am. J. Pathol. 153 (1998) 1885-1893
31. Koyama S., Sato E., Numanami H., Kubo K., Nagai S., and Izumi T. Bradykinin stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activity. Am. J. Respir. Cell Mol. Biol. 22 (2000) 75-84
32. Krieter D.H., Steinke J., Kerkhoff M., Fink E., Lemke H.D., Zingler C., Muller G.A., and Schuff-Werner P. Contact activation in low-density lipoprotein apheresis systems. Artif. Organs 29 (2005) 47-52
33. Kuoppala A., Lindstedt K.A., Saarinen J., Kovanen P.T., and Kokkonen J.O. Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma. Am. J. Physiol, Heart Circ. Physiol. 278 (2000) H1069-H1074
34. Lach E., Trifilieff A., Mousli M., Landry Y., and Gies J.P. Bradykinin-induced contraction of guinea pig lung in vitro. Naunyn Schmiedeberg's Arch. Pharmacol. 350 (1994) 201-208
35. Lauredo I.T., Forteza R.M., Botvinnikova Y., and Abraham W.M. Leukocytic cell sources of airway tissue kallikrein. Am. J. Physiol. Lung Cell. Mol. Physiol. 286 (2004) L734-L740
36. Leeb-Lundberg L.M.F., Marceau F., Müller-Esterl W., Pettibone D.J., and Zuraw B.L. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 57 (2005) 27-77
37. Liu M.C., Hubbard W.C., Proud D., Stealy B.A., Galli S.J., Kagey-Sobotka A., Bleecker E.R., and Lichtenstein L.M. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Am. Rev. Respir. Dis. 144 (1991) 51-58
38. Mak J.C., and Barnes P.J. Autoradiographic visualization of bradykinin receptors in human and guinea pig lung. Eur. J. Pharmacol. 194 (1991) 37-43
39. Morimoto H., Yamashita M., Matsuda A., Ohori M., Miyake H., and Fujii T. Characterization of dextran sulfate-induced guinea pig tracheal plasma extravasation. Jpn. J. Pharmacol. 72 (1996) 217-221
40. Nakajima N., Ichinose M., Takahashi T., Yamauchi H., Igarashi A., Miura M., Inoue H., Takishima T., and Shirato K. Bradykinin-induced airway inflammation. Contribution of sensory neuropeptides differs according to airway site. Am. J. Respir. Crit. Care Med. 149 (1994) 694-698
41. Omini C., Brunelli G., Hernandez A., and Daffonchio L. Bradykinin and substance P potentiate acetylcholine-induced bronchospasm in guinea-pig. Eur. J. Pharmacol. 163 (1989) 195-197
42. Polosa R., and Holgate S.T. Comparative airway response to inhaled bradykinin, kallidin and [des-Arg9]bradykinin in normal and asthmatic subjects. Am. Rev. Respir. Dis. 142 (1990) 1367-1371
43. Proud D., Bathon J.M., Togias A.G., and Naclerio R.M. Inhibition of the response to nasal provocation with bradykinin by HOE-140: efficacy and duration of action. Can. J. Physiol. Pharm. 73 (1995) 820-826
44. Regal J.F. Role of the complement system in pulmonary disorders. Immunopharmacology 38 (1997) 17-25
45. Ricciardolo F.L.M., Nadel J.A., Bertrand C., Yamawaki I., Chan B., and Geppetti P. Tachykinins and kinins in antigen-evoked plasma extravasation in guinea-pig nasal mucosa. Eur. J. Pharmacol. 261 (1994) 127-132
46. Sato E., Koyama S., Nomura H., Kubo K., and Sekiguchi M. Bradykinin stimulates alveolar macrophages to release neutrophil, monocyte and eosinophil chemotactic activity. J. Immunol. 157 (1996) 3122-3129
47. Siebeck M., Cheronis J.C., Fink E., Kohl J., Spies B., Spannagl M., Jochum M., and Fritz H. Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. J. Appl. Physiol. 77 (1994) 2675-2680
48. Sugahara S., Nabe T., Mizutani N., Takenaka H., and Kohno S. Kinins are involved in the development of allergic nasal hyperresponsiveness in guinea pigs. Eur. J. Pharmacol. 476 (2003) 229-237
49. Svensson C., Andersson M., Persson C.G., Venge P., Alkner U., and Pipkorn U. Albumin, bradykinins, and eosinophil cationic protein on the nasal mucosal surface in patients with hay fever during natural allergen exposure. J. Allergy Clin. Immunol. 85 (1990) 828-833
50. 2 bradykinin receptor antagonists in blocking bronchoconstriction and hypotension induced by bradykinin in anesthetized guinea pigs. J. Pharmacol. Exp. Ther. 296 (2001) 1-7
51. 2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen. J. Allergy Clin. Immunol. 107 (2001) 105-113
52. Upton R.N., and Doolette D.J. Kinetic aspects of drug disposition in the lungs. Clin. Exp. Pharmacol. Physiol. 26 (1999) 381-391
53. 2 receptor antagonist. In vivo activity on bradykinin-induced bronchoconstriction and nasal mucosa microvascular leakage in anesthetized guinea-pigs. J. Pharmacol. Exp. Ther. 315 (2005) 616-623
54. Vancheri C., Elisa G., Failla M., Mastruzzo C., Trovato Salinaro E., LoFurno D., Pistorio P.P., La Rosa C., Caruso M., and Crimi N. Bradykinin differentiates human lung fibroblasts to myofibroblast phenotype via the B2 receptor. J. Allergy Clin. Immunol. 116 (2005) 1242-1248
55. Wirth K.J., Gehring D., and Scholkens B.A. Effect of Hoe 140 on bradykinin-induced bronchoconstriction in anesthetized guinea pigs. Am. Rev. Respir. Dis. 148 (1993) 702-706